Metabolic dysfunction-associated steatotic liver disease (MASLD)

Supplements studied for metabolic dysfunction-associated steatotic liver disease (MASLD).

Overview

Inulin has limited evidence for MASLD. Oligofructose-enriched inulin at 16 g daily with weight-loss counseling for 24 weeks did not significantly reduce intrahepatic fat versus placebo but did reduce trunk fat percentage, appetite scores, and increased beneficial Bifidobacterium in the gut microbiome.

Dietary Lutein and zeaxanthin were not linked to lower MASLD risk in a study of more than 5,000 adults. It is not known whether lutein supplements have any effect. See the evidence reviews below for details.

Effect graph

Unlock now

Relevant supplements

Relevant supplements sorted by DEX Score.


Lutein	★★★★★	Low
Inulin	★★★★★	Very Low / None

Unlock now

Studies

Find individual evidence reviews for supplements sorted by DEX Score.

2 supplements for and rated at least stars. All purchase bands. No minimum star filter.

LuteinView supplement →

Reconsider purchase★★★★★

How we scored this

Effect SizeLowEvidenceLowTrustLow

Evidence Review

In a study of more than 5,000 adults, eating more lutein and zeaxanthin was not linked to a lower chance of developing MASLD (a common liver condition).
It is not known whether lutein supplements have any effect.

Browse 1 study

ObservationalAssociation between dietary intake of carotenoids and metabolic dysfunction-associated fatty liver disease in US adults: National Health and Nutrition Examination Survey 2017-March 20202024n=5,098

In 5,098 US adults, higher dietary carotenoid intake including lutein/zeaxanthin was associated with lower MAFLD odds, especially in women, adults aged 50–69, and physically active non-drinkers.

Effect: Benefit
Population: Adults
Participants: 5,098
Ages: 50–69

View on PubMed

InulinView supplement →

Do not purchase★★★★★

How we scored this

Effect SizeVery Low / NoneEvidenceLowTrustMedium

Evidence Review

Early research on metabolic dysfunction-associated steatotic liver disease is limited.
A randomized controlled trial in adults with metabolic dysfunction–associated steatotic liver disease (MASLD) which found that 24 weeks of oligofructose-enriched inulin (16 g/day) plus weight-loss counseling did not significantly reduce intrahepatic fat versus placebo, but did reduce trunk fat percentage, appetite scores, and increased beneficial Bifidobacterium abundance in the gut microbiome.
More studies are needed before any benefit can be considered reliable.

Browse 1 study

RCTEffects of combined prebiotic fiber supplementation and weight loss counseling in adults with metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial2025n=22

A randomized controlled trial in adults with metabolic dysfunction–associated steatotic liver disease (MASLD) which found that 24 weeks of oligofructose-enriched inulin (16 g/day) plus weight-loss counseling did not significantly reduce intrahepatic fat versus placebo, but did reduce trunk fat percentage, appetite scores, and increased beneficial Bifidobacterium abundance in the gut microbiome.

Effect: No Benefit
Duration: 24 weeks
Dose: 16 g/day
Population: Adults
Participants: 22
Ages: 18–70

View on PubMed

Unlock now

Evidence visualised

Same ratings as above, aggregated so you can see coverage and imbalance.

Purchase-guidance distribution

How many supplements fall in each purchase band

Effect-size distribution

How large the reported benefits tend to be

Study distribution across 2 supplements for metabolic dysfunction-associated steatotic liver disease (masld) (2 studies total).
Supplement	DEX	Studies	Meta-analyses	Share
Inulin	★★★★★32%	1	0	50%
Lutein	★★★★★40%	1	0	50%

Unlock now

Metabolic dysfunction-associated steatotic liver disease (MASLD)

Overview

Effect graph

Relevant supplements

Studies

Evidence visualised

On this page